Clinical trials: Onchocerciasis (River Blindness)
Loiasis With Positive Blood Microfilaremia, Loiasis
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
- Trial name
- STOP-FiLAR-ALB (NCT06613997)
- Testing
- Albendazole 400mg
- Volunteers
- 100 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Onchocerciasis
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
The DOLF Ocular Changes after Ivermectin study will investigate the kinetics of O. volvulus microfilaria (Mf) in the eye following treatment with ivermectin.
- Trial name
- NCT03517462
- Testing
- Ivermectin 3Mg Tab
- Where
- Ghana
- Volunteers
- 231 people
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
- Trial name
- NCT00127504
- Testing
- Rifampin, Azithromycin
- Where
- Guatemala
- Volunteers
- 80 people
- Sponsor
- Centers for Disease Control and Prevention
Onchocerciasis
Pediatric Pharmacokinetics And Safety Study Of Moxidectin
The purpose of this study is to measure the amount of moxidectin in subjects' blood and to measure safety. This study will enroll 36 children aged 4 to 11 years (>=12 kg) with or without Onchocerca volvulus (O volvulus)…
- Trial name
- NCT01035619
- Testing
- moxidectin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Nodding Syndrome, Epilepsy
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
Background: Childhood epilepsy disorders are particular frequent in the area around Mahenge, southern Tanzania and recent studies have described a novel type of epilepsy with repetitive head nodding episodes and often progressive…
- Conditions
- Nodding Syndrome, Epilepsy, Onchocerciasis, Cognitive Impairment
- Trial name
- NSEC (NCT03653975)
- Testing
- no intervention
- Where
- Tanzania
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Lymphatic Filariasis, Onchocerciasis
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Approximately 5,200 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- DOLF-LIBERIA (NCT01905436)
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
- Where
- Liberia
- Volunteers
- 21,862 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Safety and Efficacy of IDA for Onchocerciasis
This DOLF study will investigate the safety and effectiveness of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and…
- Trial name
- DOLF IDA/Oncho (NCT04188301)
- Testing
- IVM w/ ALB, Single dose of IDA, Three daily doses of IDA
- Where
- Ghana
- Volunteers
- 154 people
- Sponsor
- Washington University School of Medicine
Filariasis, Lymphatic, Onchocerciasis
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Lymphatic filariasis and onchocerciasis are a group of neglected tropical diseases caused by the transmission of worm larvae (microfilaria) by biting insects.
- Trial name
- AWOL (NCT05084560)
- Testing
- AWZ1066S
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Onchocerciasis, Loiasis
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
This study aims at evaluating the diagnosis performances of the LTS-2 DEC patch for onchocerciasis compared to the gold standard which are the skin snips.
- Conditions
- Onchocerciasis, Loiasis, Diagnoses Disease, Neglected Diseases
- Trial name
- EOLoa (NCT04035174)
- Testing
- LTS-2 DEC patch, Skin snips
- Where
- Cameroon
- Volunteers
- healthy volunteers welcome
- Sponsor
- Center for Research on Filariasis and Other Tropical Diseases, Cameroon
Onchocerciasis, Loiasis
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases.
- Conditions
- Onchocerciasis, Loiasis, Mansonelliasis, Healthy Volunteers
- Trial name
- Obi1 (NCT06350851)
- Testing
- Biological samples collection (blood drawing + feces)
- Where
- Cameroon
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Bioaster
Epilepsy
Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy
Randomized clinical trial in the Logo health zone, in Ituri province, Democratic Republic of Congo to compare seizure freedom in onchocerciasis infested epilepsy patients who ivermectin treatment once a year compared to 2 and 3…
- Trial name
- OAETREATe (NCT03852303)
- Testing
- ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 197 people
- Sponsor
- Universiteit Antwerpen
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariases, Onchocerciasis
Prevalence of LF Infection in Districts Not Included in LF Control Activities
Lymphatic filariasis is a neglected tropical disease earmarked for elimination as a public health problem by the year 2020. Since the year 2000, the Global Program for the Elimination of LF has together with endemic countries…
- Trial name
- NCT03131401
- Testing
- Diagnosis of lymphatic filariasis, Diagnosis of lymphatic Filariasis and onchocerciasis, DEC Patch
- Where
- Ghana
- Volunteers
- 3,736 people
- Sponsor
- Noguchi Memorial Institute for Medical Research
Onchocerciasis, Ocular, Loiasis
Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.
- Trial name
- EOLoa (NCT04049630)
- Testing
- LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg
- Where
- Republic of the Congo
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Healthy Volunteers
First in Man Clinical Trial of Emodepside (BAY 44-4400)
This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.
- Trial name
- NCT02661178
- Testing
- emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Onchocerciasis
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O.
- Trial name
- NCT03876262
- Testing
- Moxidectin, Ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 323 people
- Sponsor
- Medicines Development for Global Health
Filariasis, Helminthiasis
Host Response to Infection and Treatment in Filarial Diseases
This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment.
- Conditions
- Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis
- Trial name
- NCT00001230
- Testing
- Diethylcarbamazine
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness.
- Trial name
- NCT00790998
- Testing
- Moxidectin, Ivermectin
- Where
- 4 sites in Democratic Republic of the Congo, Ghana and 1 more
- Volunteers
- 1,497 people
- Sponsor
- Medicines Development for Global Health
Onchocerciasis
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Onchocerciasis is a major public health problem in affected countries that causes disease-induced disability, and overall loss of economic productivity.
- Trial name
- NCT04913610
- Testing
- ABBV-4083, Albendazole
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 153 people
- Sponsor
- AbbVie